Movano Health Q1 2023 net loss $7.1M; Evie Ring launch planned September at $269

Corvex, Inc.

2023-Q1 EPS reported -$0.19

Net loss of $7.1M ($0.19 per share) in Q1 2023 vs $6.9M loss in Q1 2022; no revenue generated.
Evie Ring to launch September 2023 at $269 with no subscription; 510(k) submission for heart rate/SpO2 expected June 2023.
Over 80,000 sign-ups and nearly 500,000 website visits since Evie Ring announcement at CES in January 2023.
Completed first beta programs with four partners; second beta round by early July includes global athletic apparel company.
Completed blood pressure clinical trial with 50+ subjects using proprietary RF single-chip solution; glucose trial planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvex, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Movano Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Corvex, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-039342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.